Daniel Heng
MD, MPH
Professor of Medicine
👥Biography 个人简介
Daniel Heng developed the IMDC (Heng) risk criteria that became the global standard for prognostic stratification in metastatic RCC. His population-based research and real-world evidence studies have informed treatment decisions and clinical trial design. He continues to refine prognostic tools and evaluate outcomes of novel agents including belzutifan.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Daniel Heng 的研究动态
Follow Daniel Heng's research updates
留下邮箱，当我们发布与 Daniel Heng（Tom Baker Cancer Centre / University of Calgary）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment